Triatomic Capital

Triatomic Capital is an early-stage venture capital firm focusing on "century-defining" technologies. The firm invests in deep tech sectors like engineered biology (including cell and gene therapies, synthetic biology, and AI-driven drug discovery), energy innovations (battery tech, nuclear fusion), and advanced computing (AI processors, quantum computing). Their mission is to support startups that push the boundaries in areas critical to future industries, including digital infrastructure, automation, and nanomaterials. Triatomic operates from offices in New York, San Francisco, and Hong Kong, giving it a broad geographical reach. The firm typically participates in Seed to Series A rounds, with check sizes ranging from $250K to $25M, though they don’t always lead investment rounds. Recent high-profile investments include Chemify, which leverages AI to digitize chemical discovery, and Betteromics, a bioinformatics platform for life sciences. The leadership team, co-founded by Jeff Huber, former Google executive and founding CEO of GRAIL, brings extensive experience in scaling tech and biotech companies. Huber’s background in applying AI and leading life-saving innovations plays a pivotal role in guiding Triatomic's investment strategy.